Pharmacological Immunomodulation In Emergency Medicine: Therapeutic Strategies And Clinical Challenges
International Journal of Drug Delivery Technology · 25.05.2026 · 16 (36s)
DOI: 10.25258/ijddt.16.36s.4 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, erschienen am 25.05.2026. Verfasst von Karen Gabriel Macías- Sánchez und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Pharmacological immunomodulation has become an increasingly relevant therapeutic dimension in emergency medicine because many acute syndromes are driven not only by infection, trauma, hypoxia, or toxic exposure, but also by maladaptive host immune responses. This narrative critical review analyzed immunomodulatory strategies applicable to emergency care, including corticosteroids, cytokine inhibitors, JAK inhibitors, intravenous immunoglobulin, complement inhibitors, anticoagulant–anti-inflammatory approaches, and immune-restorative therapies. The strongest current evidence supports corticosteroids in selected patients with septic shock, acute respiratory distress syndrome, and severe bacterial communityacquired pneumonia, while high-dose short-duration corticosteroids in septic shock should be avoided. Evidence from the CAPE COD trial further supports early hydrocortisone in severe community-acquired pneumonia requiring intensive care, showing lower 28-day mortality compared with placebo. The main clinical challenge is that emergency physicians must often decide before immune phenotyping, microbiology, or advanced biomarkers are available. Sepsis guidelines emphasize immediate recognition, antimicrobials, source control, and hemodynamic stabilization; therefore, immunomodulation must function as an adjunct rather than a replacement for core resuscitative care. Future progress depends on rapid biomarker-guided algorithms, emergency department–based trials, and phenotype-specific protocols capable of distinguishing hyperinflammation, sterile injury, allergic mediator release, immunothrombosis, and immune paralysis. This review concludes that immunomodulation in emergency medicine should be individualized, time-sensitive, safety-conscious, and integrated into structured acute-care pathways
Zitieren
APA
Sánchez, K. G. M., Estrada, C. C., & Herrera, L. C. O. (2026). Pharmacological Immunomodulation In Emergency Medicine: Therapeutic Strategies And Clinical Challenges. International Journal of Drug Delivery Technology, 16(36s). https://doi.org/10.25258/ijddt.16.36s.4
Vancouver
Sánchez KGM, Estrada CC, Herrera LCO. Pharmacological Immunomodulation In Emergency Medicine: Therapeutic Strategies And Clinical Challenges. International Journal of Drug Delivery Technology. 2026;16(36s). doi:10.25258/ijddt.16.36s.4
BibTeX
@article{Snchez2026,
author = {Sánchez, Karen Gabriel Macías- and Estrada, Carolina Campos- and Herrera, Luis Carlos Orjuela},
title = {Pharmacological Immunomodulation In Emergency Medicine: Therapeutic Strategies And Clinical Challenges},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {36s},
doi = {10.25258/ijddt.16.36s.4}
}
EUVIMED